CTMX - CytomX Therapeutics, Inc.
| Previous Close | 14.87 |
| Open | 14.49 |
| Bid | 0.00 x 1100 |
| Ask | 0.00 x 1300 |
| Day's Range | 14.27 - 15.34 |
| 52 Week Range | 13.54 - 35.00 |
| Volume | 235,265 |
| Avg. Volume | 376,920 |
| Market Cap | 670.409M |
| Beta (3Y Monthly) | 0.85 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.01 |
| Earnings Date | Nov 5, 2018 - Nov 9, 2018 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 36.13 |
- GlobeNewswire•2 days ago
CytomX Therapeutics Presents Clinical Data from Probody™ Platform and CX-072 at 2018 ESMO Annual Meeting
- Additional Data Supports PD-L1 Targeting Probody CX-072 as Well Tolerated with Antitumor Activity as Monotherapy and in Combination with Ipilimumab - - Company to Host.
- GlobeNewswire•12 days ago
Factors of Influence in 2018, Key Indicators and Opportunity within Cloud Peak Energy, Ralph Lauren, CytomX Therapeutics, Extreme Networks, Heron Therapeutics, and Alteryx — New Research Emphasizes Economic Growth
NEW YORK, Oct. 12, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
- GlobeNewswire•15 days ago
CytomX Therapeutics Announces Presentations at 2018 ESMO Annual Meeting
SOUTH SAN FRANCISCO, Calif., Oct. 08, 2018 -- CytomX Therapeutics, Inc. (Nasdaq:CTMX) a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of.
- Simply Wall St.•19 days ago
How Does CytomX Therapeutics Inc (NASDAQ:CTMX) Affect Your Portfolio Returns?
If you own shares in CytomX Therapeutics Inc (NASDAQ:CTMX) then it’s worth thinking about how it contributes to the volatility of your portfolio, overall. In finance, Beta is a measure Read More...
- GlobeNewswire•29 days ago
CytomX to Present at Upcoming Healthcare Conferences
SOUTH SAN FRANCISCO, Calif., Sept. 25, 2018 -- CytomX Therapeutics, Inc. (Nasdaq:CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of.
- Zacks•2 months ago
CytomX Therapeutics (CTMX) Reports Q2 Loss, Tops Revenue Estimates
CytomX Therapeutics (CTMX) delivered earnings and revenue surprises of -2.94% and 29.52%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
- Associated Press•2 months ago
CytomX Therapeutics: 2Q Earnings Snapshot
The South San Francisco, California-based company said it had a loss of 35 cents per share. The results fell short of Wall Street expectations. The average estimate of three analysts surveyed by Zacks ...
- GlobeNewswire•2 months ago
CytomX Therapeutics Announces Second Quarter 2018 Financial Results
-Presentation of First-in-Human Data Demonstrated Encouraging Safety and Efficacy Profile of CX-072 as Monotherapy and in Combination with ipilimumab-. -Preliminary Proof-of-Concept for Probody™ Platform ...
- GlobeNewswire•3 months ago
CytomX to Present at the 2018 Wedbush PacGrow Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Aug. 07, 2018-- CytomX Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics based ...
- GlobeNewswire•3 months ago
Report: Developing Opportunities within OMNOVA Solutions, Natural Health Trends, Vocera Communications, Oppenheimer, CytomX Therapeutics, and The Ultimate Software Group — Future Expectations, Projections Moving into 2018
NEW YORK, Aug. 03, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of OMNOVA ...
- GlobeNewswire•3 months ago
CytomX Therapeutics to Announce Second Quarter 2018 Financial Results
SOUTH SAN FRANCISCO, Calif., July 30, 2018-- CytomX Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics based ...
- ACCESSWIRE•4 months ago
Free Technical Research on Edge Therapeutics and Three More Biotech Equities
On Friday, July 6, 2018, the NASDAQ Composite, the Dow Jones Industrial Average, and the S&P 500 edged higher at the closing bell. All sectors ended Friday's trading session in bullish territories. Taking into consideration last Friday's market sentiment, WallStEquities.com assessed the following Biotechnology equities this morning: CytomX Therapeutics Inc. (NASDAQ: CTMX), Dynavax Technologies Corp. (NASDAQ: DVAX), Edge Therapeutics Inc. (NASDAQ: EDGE), Editas Medicine Inc. (NASDAQ: EDIT).
- ACCESSWIRE•5 months ago
Wired News – CytomX Gets FDA Approval for Investigational New Drug Application, Triggers $25 Million Milestone Payment from AbbVie
LONDON, UK / ACCESSWIRE / May 24, 2018 / If you want access to our free research report on CytomX Therapeutics, Inc. (NASDAQ: CTMX), all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=CTMX as the Company's latest news hit the wire. On May 22, 2018, the Company announced that the US Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for CX-2029, a first-in-class CD71-directed Probody™ drug conjugate being co-developed by CytomX and its partner AbbVie Inc. (NYSE: ABBV).
- Associated Press•5 months ago
CytomX Therapeutics: 1Q Earnings Snapshot
On a per-share basis, the South San Francisco, California-based company said it had a loss of 40 cents. The results fell short of Wall Street expectations. The average estimate of five analysts surveyed ...
